Protagonist Therapeutics Starts Phase 1 Trial of Potential Ulcerative Colitis Treatment PN-10943

Protagonist Therapeutics Starts Phase 1 Trial of Potential Ulcerative Colitis Treatment PN-10943
Protagonist Therapeutics has begun dosing patients in a Phase 1 clinical trial of an oral ulcerative colitis (UC) treatment candidate known as PN-10943, the company announced in a press release. PN-10943 is a gut-restricted blocker of a protein called alpha-4-beta-7 integrin, an adhesion molecule that regulates the migration and homing of lymphocytes (immune cells) to gut-associated lymphoid tissue (GALT). The GALT contains immune T- and B-cells that protect against pathogens. The Phase 1
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *